57 Generally, studies have been congruous with this one, suggesting a very low rate of clinically significant hypotension with Tadalista with or witho
48 Generally, the incidence of these side effects declines over time on chronic therapy. 42 , 52 Although the effects may be mild, it should be noted that the prolonged half-life of Tadalista may tend to produce side effects of longer duration compared with PDE5I with shorter half-lives. 21 , 42 Serious side effects have not been reported in some studies; in studies where serious events occurred, the effect was considered not to be related to the study drug itself.
More importantly, improvements in the IIEF-EF of Tadalista-treated men were positively correlated to the satisfaction with treatment in their female partners. There was a significantly greater change in mean sexual life quality in the Tadalista-treated men relative to controls (+39 vs +12, respectively) and in female partners of treated men relative to partners of controls (+32 vs +5, respectively). In a follow-up data set based on the prior work reported by Rubio-Aurioles et al, 52 Seftel et al 53 reported on variables pertaining to overall sexual satisfaction in Tadalista-treated men and their female partners.
Men and their partners in the treatment group reported significantly greater improvements in sexual quality of life and quality of treatment relative to placebotreated couples based on validated instruments. Men treated with Tadalista endorsed significantly greater improvements in IIEF-EF score (+7.9 vs +0.7 in the treatment and placebo groups) and changed to an affirmative response to SEP2 (29% and 3%, respectively) and SEP3 (46% vs 11%, respectively). Of note, partners were prescreened using the Female Sexual Function Index (FSFI); partners with FSFI total scores less than 26.55 (suggestive of high risk of female sexual dysfunction) were excluded from the subsequent analysis.
Rubio-Aurioles et al 52 reported on partners' satisfaction in a multicenter, parallel group RDBPCS of 5 mg Tadalista daily vs placebo for 12 weeks for men with ED, most of whom had the condition for more than 1 year. A partner preference study of on-demand sildenafil vs Tadalista indicated that 79% of female partners preferred Tadalista, citing a more relaxed approach to sexual intimacy and greater flexibility with respect to timing of intercourse. Tadalista appeared to have beneficial effects on LUTS severity at all dosages although this was not associated with any clinically significant changes in objective urodynamic parameters (urine flow rate and postvoid residual PVR urine volume), with the exception of a statistically significant (but likely clinically meaningless) increase in PVR volume in the 2.5 mg group relative to the placebo group.
Importantly, the frequency of sexual intercourse attempts was not significantly different between the treatment groups throughout the study.